Month: September 2020

ROCHESTER, Mich., Sept. 21, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will resume its webinar series this week with a panel of industry experts and thought leaders presenting innovative ideas for improving medication launches.OptimizeRx is presenting this webinar in collaboration with the Digital Health Coalition and Diligent Health Solutions. The organizations have teamed up to address pain points in patient adherence to new medications that present undesirable side-effects. The discussion will focus on ways life science companies can deliver more effective programs for such medications, and achieve better outcomes for patients and their care teams.A panel of industry experts will discuss a new case study of an innovative...

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted rare pediatric disease designation (“RPD”) for CRN04777, an investigational, orally available, nonpeptide somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). Congenital HI is a devastating rare disease in which infants are born with life threatening hypoglycemia (low blood glucose) due to excess insulin secretion.“Congenital HI is a serious condition of neonates, infants, and children. Failure to recognize and effectively treat...

LAVAL, Québec, Sept. 21, 2020 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, is pleased to announce the appointment of Stephen Reitknecht as Chief Financial Officer of Savaria effective September 21, 2020.“Mr. Reitknecht holds a C.P.A. with 15 years’ experience in a range of industries including medical devices and wholesale distribution. He brings strong knowledge for multi-currency consolidation, back office integration, IFRS and US GAAP, and acquisition integration. Mr. Reitknecht will work primarily from the manufacturing operation in Brampton, Ontario, Canada where both the Corporation’s Vice-President of Operations and CEO are stationed,” stated Marcel Bourassa, President and Chief Executive Officer of Savaria.“I am enthusiastic about joining Savaria and...

LAVAL, Québec, 21 sept. 2020 (GLOBE NEWSWIRE) — Corporation Savaria (« Savaria ») (TSX : SIS) un des chefs de file mondiaux de l’industrie de l’accessibilité, a le plaisir d’annoncer la nomination de M. Stephen Reitknecht au poste de chef de la direction financière de Savaria, effectif le 21 septembre 2020.Mot du président« M. Reitknecht est titulaire d’un C.P.A. et possède 15 ans d’expérience dans divers secteurs, notamment les équipements médicaux et la distribution en gros. Il apporte de solides connaissances en consolidation multidevises, intégration d’équipes de soutien, normes IFRS et US GAAP et intégration d’acquisitions. M. Reitknecht travaillera principalement à partir de l’usine de fabrication de Brampton, en Ontario, Canada, où le vice-président des opérations et le chef de la direction de la société sont...

$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by IncyteROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $15 million milestone payment has been triggered under its exclusive global collaboration and license agreement with Incyte for retifanlimab (MGA012), an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA00012). The milestone was triggered by the initiation of the Phase 3 POD1UM-304 clinical trial, evaluating the efficacy and safety of retifanlimab with platinum-based chemotherapy in patients with metastatic squamous and non-squamous...

Topline proof-of-concept results in ADH1 anticipated in 2021Currently, there are no approved therapies for ADH1PALO ALTO, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center study of encaleret (CLTX-305) in individuals with ADH1 conducted at the National Institutes of Health. ADH1 is a rare, inherited disease caused by gain-of-function mutations in the calcium sensing receptor (CaSR) resulting in abnormally low serum calcium and high urine calcium and a range of debilitating symptoms. Encaleret sulfate is an investigational oral therapy being studied to address ADH1 at its source by antagonizing the CaSR.“Patients with ADH1 are currently treated with calcium supplements with a goal of raising their serum calcium...

CALGARY, Alberta, Sept. 21, 2020 (GLOBE NEWSWIRE) — TC Energy Corporation (TSX, NYSE:TRP) (TC Energy or the Company) today announced Russ Girling’s retirement as President and Chief Executive Officer and from its Board of Directors effective December 31, 2020. François Poirier, currently Chief Operating Officer, President, Power & Storage and Mexico, will succeed Mr. Girling as President and Chief Executive Officer and will join the Board January 1, 2021. Mr. Girling will assist Mr. Poirier with the transition through February 28.“On behalf of all Board members, I would like to thank Russ for his invaluable contributions to the Company,” says Siim Vanaselja, Chairman of the Board of Directors. “Over the last decade, he has led TC Energy through a period of unprecedented growth and transformation, including the development of...

Chicago, IL, Sept. 21, 2020 (GLOBE NEWSWIRE) — FOMO CORP. (US OTC: ETFM)–Under an LOI to merge with FOMO this Fall, Purge Virus LLC (PV) is pleased to announce its Clean Room Initiative (CRI) to help home and business owners at risk from Western U.S. wildfires. For more on the portable devices see: https://purgevirus.com/portable-devices/According to the Lawrence Berkley National Laboratory, “People in the U.S. and many other developed countries are indoors approximately 90% of the time, and may be indoors even more when outdoor air is affected by wildfires When outdoor air particle concentrations increase, indoor air concentrations of particles also increase, particularly in homes because they usually have low efficiency particle filtration systems or no particle filtration.”The recent wildfires have caught the attention of the world,...